Imlunestrant Mechanism of Action Animation for Estrogen Receptor-Positive (ER+) Breast Cancer

Imlunestrant is an oral selective estrogen receptor degrader (SERD) developed by Eli Lilly and Company, designed to treat estrogen receptor-positive (ER+) breast cancer. Estrogen receptor-positive breast cancer is a common subtype of breast cancer, characterized by the presence of estrogen receptors on tumor cells. These receptors promote cancer cell growth when activated by estrogen.

Imlunestrant Mechanism of Action

The animation by Ghost Medical for Eli Lilly effectively visualizes Imlunestrant’s mechanism of action. It compares normal estrogen binding with Imlunestrant’s effects on the estrogen receptor, showing the intricate cellular processes involved. Under normal circumstances, estrogen binds to estrogen receptors within the cell, initiating transcriptional activity in the nucleus and promoting cancer cell growth. The animation demonstrates how Imlunestrant competes with estrogen for receptor binding, disrupting this process. Once bound, Imlunestrant facilitates the degradation of the estrogen receptor, effectively blocking the cancer-promoting signaling pathway.

Imlunestrant Animation Features:

The animation creatively incorporates cellular components such as the nucleus, cell membrane, and estrogen receptors to depict the contrast between normal and drug-mediated receptor activity. By visualizing estrogen’s effect on cell proliferation and Imlunestrant’s disruption of this process, the animation educates healthcare professionals and patients on the drug’s therapeutic potential.